地西他滨治疗脑膜瘤疗效的分子预测因子——一项先导研究
该先导研究在13株原代脑膜瘤细胞中分析地西他滨(DCT)对增殖和活力的影响,8株(62%)在48小时药物暴露后有效(p < .05),DCT敏感细胞的DNMT1中位降幅(-50.5%)大于耐药细胞(-11.1%,p = .030),患者年龄、性别、组织学亚型、肿瘤位置、Ki67、DNMT1及所分析癌基因表达与疗效均无显著相关(p > .05)。
要点
- 地西他滨10µM在13株脑膜瘤细胞中8株(62%)48小时有效(p < .05)。
- DCT敏感细胞DNMT1中位降幅-50.5%,耐药细胞-11.1%(p = .030)。
- 72小时后有效细胞株比例降至25%,提示可能需要重复暴露。
核心结论
- 地西他滨在脑膜瘤中的早期效应与DNMT1表达密切相关,而临床、组织学和分子层面的疗效预测因子稀少。
- 药物疗效的动力学可能提示需要重复暴露,并鼓励进一步分析。
研究设计与样本
- 先导研究,在13株原代脑膜瘤细胞中通过免疫荧光和MTT法分析地西他滨对增殖和活力的影响,并将病例分为药物有效组和无效组。
- 采用免疫荧光检测Ki67、DNMT1及五种癌基因(TRIM58、FAM84B、ELOVL2、MAL2、LMO3)表达,并进行全基因组DNA甲基化分析以探索疗效的分子前提。
主要发现
- 地西他滨10µM在药物暴露48小时后对13株脑膜瘤细胞中的8株(62%)有效(p < .05)。
- 地西他滨显著降低除两株外所有细胞株的DNMT1表达,药物暴露48小时后DNMT1中位降幅在DCT耐药细胞为-11.1%,在DCT敏感细胞为-50.5%(p = .030)。
- 对地西他滨暴露有反应的细胞株比例在72小时后明显降至25%。
- 患者年龄、性别、组织学亚型、原发肿瘤位置、Ki67、DNMT1或所分析癌基因的表达与治疗反应均无显著相关性(每项p > .05)。
- 地西他滨疗效与原发肿瘤的甲基化类别和整体DNA甲基化无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Effective chemotherapeutical agents for the treatment of meningiomas are still lacking. Previous in-vitro analyses revealed efficacy of decitabine (DCT), a DNA methyltransferase (DNMT) inhibitor established in the treatment of leukemia, in a yet undefined subgroup of meningiomas. METHODS: Effects of DCT on proliferation and viability was analyzed in primary meningioma cells by immunofluorescence and MTT assays, and cases were classified as drug responders and non-responders. Molecular preconditions for efficacy were analyzed using immunofluorescence for Ki67, DNMT1, and five oncogenes (TRIM58, FAM84B, ELOVL2, MAL2, LMO3) previously found to be differentially methylated after DCT exposition, as well as by genome-wide DNA methylation analyses. RESULTS: Efficacy of DCT (10µM) was found in eight (62%) of 13 meningioma cell lines 48 h after drug exposition (p < .05). DCT significantly reduced DNMT1 expression in all but two cell lines, and median ΔDNMT1 reduction 48 h after drug exposition was lower in DCT-resistant (-11.1%) than in DCT-sensitive (-50.5%, p = .030) cells. Rates of cell lines responsive to DCT exposition distinctly decreased to 25% after 72 h. No significant correlation of the patients´ age, sex, histological subtype, location of the paternal tumor, expression of Ki67, DNMT1 or the analyzed oncogenes with treatment response was found (p > .05, each). DCT efficacy was further independent of the methylation class and global DNA methylation of the paternal tumor. CONCLUSION: Early effects of DCT in meningiomas are strongly related with DNMT1 expression, while clinical, histological, and molecular predictors for efficacy are sparse. Kinetics of drug efficacy might indicate necessity of repeated exposition and encourage further analyses.
引用
- Spille DC, Thomas C, Wagner A, et al. Molecular predictors for decitabine efficacy in meningiomas - a pilot study. J Neurooncol. 2023. PMID: 37477823. doi:10.1007/s11060-023-04379-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。